SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVIGEN(avgn)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JMarcus who wrote (209)5/30/2002 1:29:31 PM
From: JMarcus  Read Replies (1) of 228
 
From the May 27th issue of Barron's:

<<Sjostrom also is intrigued by Avigen, a leader in gene therapy, which involves using defanged viruses to deliver healthy DNA to correct the faulty DNA of people suffering from genetic diseases, such as hemophilia. There are doubts about the general effectiveness of gene therapy, but at 9, Avigen trades near its net cash reserves of $7 a share.>>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News